Jaguar Health Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal diseases, primarily for patients with chronic, debilitating conditions. The company emphasizes its commitment to using natural products derived from plants to create treatments, with a particular focus on improving the quality of life for those suffering from gastrointestinal disorders. By harnessing the power of botanical medicines, Jaguar Health aims to address both the symptoms and the underlying causes of these conditions, supporting patient wellness and enhancing standard care practices. Read More
SAN FRANCISCO, CA / ACCESS Newswire / March 11, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, March 12, 2026 at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com.
As announced, Jaguar received an up-front payment of $16M of non-dilutive capital in January 2026 upon entering U.S. license agreement with Future Pak for Mytesi® and Canalevia®-CA1 - Jaguar's two commercialized crofelemer drugs - an agreement that is fully aligned with company's strategy to concentrate crofelemer development efforts on human rare-disease intestinal failure indications
Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future payments
SAN FRANCISCO, CA / ACCESS Newswire / January 14, 2026 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will present virtually on Thursday, January 15, 2026 at the Lytham Partners Healthcare Investor Summit.
Article discusses results demonstrating parenteral support (PS) reduction ranging from 12 to 37% in ongoing proof-of-concept study of crofelemer in pediatric patients with intestinal failure
